Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 80

1.

Type I diabetes-associated tolerogenic properties of interleukin-2.

Chentoufi AA, Gaudreau S, Nguyen A, Sabha M, Amrani A, Elghazali G.

Clin Dev Immunol. 2011;2011:289343. doi: 10.1155/2011/289343. Epub 2011 May 10.

2.

Control of type 1 autoimmune diabetes by naturally occurring CD4+CD25+ regulatory T lymphocytes in neonatal NOD mice.

Piccirillo CA, Tritt M, Sgouroudis E, Albanese A, Pyzik M, Hay V.

Ann N Y Acad Sci. 2005 Jun;1051:72-87. Review.

PMID:
16126946
3.

IL-7 uniquely maintains FoxP3(+) adaptive Treg cells that reverse diabetes in NOD mice via integrin-β7-dependent localization.

Li CR, Deiro MF, Godebu E, Bradley LM.

J Autoimmun. 2011 Nov;37(3):217-27. doi: 10.1016/j.jaut.2011.06.002. Epub 2011 Jul 13.

4.
5.
7.

Genetic and therapeutic control of diabetogenic CD8+ T cells.

Santamaria P.

Novartis Found Symp. 2008;292:130-6; discussion 136-45, 202-3.

PMID:
19209463
8.

Roles of cytokines in the pathogenesis and therapy of type 1 diabetes.

Rabinovitch A, Suarez-Pinzon WL.

Cell Biochem Biophys. 2007;48(2-3):159-63.

PMID:
17709885
9.

The crucial role of IL-2/IL-2RA-mediated immune regulation in the pathogenesis of type 1 diabetes, an evidence coming from genetic and animal model studies.

Chistiakov DA, Voronova NV, Chistiakov PA.

Immunol Lett. 2008 Jun 15;118(1):1-5. doi: 10.1016/j.imlet.2008.03.002. Epub 2008 Apr 1. Review.

PMID:
18417224
10.

A novel mechanism of regulatory T cell-mediated down-regulation of autoimmunity.

Qin HY, Mukherjee R, Lee-Chan E, Ewen C, Bleackley RC, Singh B.

Int Immunol. 2006 Jul;18(7):1001-15. Epub 2006 May 4.

PMID:
16675487
11.

Autologous regulatory T cells for the treatment of type 1 diabetes.

Thompson JA, Perry D, Brusko TM.

Curr Diab Rep. 2012 Oct;12(5):623-32. doi: 10.1007/s11892-012-0304-5. Review.

PMID:
22843491
12.

TGF-beta-dependent mechanisms mediate restoration of self-tolerance induced by antibodies to CD3 in overt autoimmune diabetes.

Belghith M, Bluestone JA, Barriot S, Mégret J, Bach JF, Chatenoud L.

Nat Med. 2003 Sep;9(9):1202-8. Epub 2003 Aug 24.

PMID:
12937416
13.

Advances in type I diabetes associated tolerance mechanisms.

Chentoufi AA, Binder NR, Berka N, Abunadi T, Polychronakos C.

Scand J Immunol. 2008 Jul;68(1):1-11. doi: 10.1111/j.1365-3083.2008.02120.x. Epub 2008 May 9. Review.

14.
15.

Thymic self-antigen expression for the design of a negative/tolerogenic self-vaccine against type 1 diabetes.

Chentoufi AA, Geenen V.

Clin Dev Immunol. 2011;2011:349368. doi: 10.1155/2011/349368. Epub 2011 May 23.

16.

Transfusion of apoptotic beta-cells induces immune tolerance to beta-cell antigens and prevents type 1 diabetes in NOD mice.

Xia CQ, Peng R, Qiu Y, Annamalai M, Gordon D, Clare-Salzler MJ.

Diabetes. 2007 Aug;56(8):2116-23. Epub 2007 May 11.

17.

Re-establishing immune tolerance in type 1 diabetes via regulatory T cells.

Gregori S, Battaglia M, Roncarolo MG.

Novartis Found Symp. 2008;292:174-83; discussion 183-6, 202-3.

PMID:
19203099
19.

Control of type 1 diabetes by CD4+Foxp3+ regulatory T cells: lessons from mouse models and implications for human disease.

Sgouroudis E, Piccirillo CA.

Diabetes Metab Res Rev. 2009 Mar;25(3):208-18. doi: 10.1002/dmrr.945. Review.

PMID:
19214972
20.

Protection from type 1 diabetes by invariant NK T cells requires the activity of CD4+CD25+ regulatory T cells.

Ly D, Mi QS, Hussain S, Delovitch TL.

J Immunol. 2006 Sep 15;177(6):3695-704.

Supplemental Content

Support Center